SPY 130
Alternative Names: PR-026; SPY-130Latest Information Update: 14 Mar 2024
Price :
$50 *
At a glance
- Originator Paragon Therapeutics
- Developer Paragon Therapeutics; Spyre Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 07 Mar 2024 Spyre Therapeutics plans to initiate combination toxicology studies in 2025
- 31 Dec 2023 Preclinical trials in Inflammatory bowel diseases in USA (SC)
- 14 Jul 2023 Early research in Inflammatory bowel diseases in USA (SC) (Paragon Therapeutics pipeline, July 2023) (Spyre Therapeutics website - July 2023)